PIVI’s Work with Mongolia
Mongolia joined PIVI in 2016. Mongolia’s first vaccination campaign prioritized healthcare workers and staff in emergency agencies. The campaign was highly successful, as 100% of the 45,000 doses were administered successfully. During the coming flu season, Mongolia plans to vaccinate 125,000 people. The focus risk groups include: pregnant women, children ages two-five and health workers. Second tier risk groups include chronic disease patients and emergency staff. PIVI is donating 80,000 doses for this campaign, and the Ministry of Health of Mongolia has purchased 45,000 doses.
Mongolia’s continued purchase of vaccine doses through the Ministry of Health is laying the foundation for a sustainable seasonal influenza program. Working with PIVI, they completed a sustainability plan this summer.
With PIVI support, Mongolia developed an animated television short advocating for vaccination that has been broadcast on five TV channels and embedded on three websites.
Mongolia hosted an advocacy meeting with key decision-makers from the ministry of health, the national immunization technical advisory group, the National Influenza Center of Mongolia, and the National Department of Communicable Diseases to discuss the impact of flu vaccination. Mongolia completed a national survey of adverse events following flu immunization (AEFI). They conducted an active follow up of 6,943 people, 15% of the total number of people who were recipients of Protein Science’s Flublok vaccine, the first recombinant protein influenza vaccine approved by the U.S. FDA for persons 18 and older. The country has also completed a nationwide survey of factors affecting vaccine uptake pregnant women and the general public who accept and decline flu vaccination. Mongolia has also conducted a formal, enhanced surveillance of adverse events following immunization among pregnant women recipients of Flublok vaccine and is currently analyzing the data.